Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 28, 2022Liver CancerOpen Access

IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study

View Full Paper
Ask AI
Bookmark
Share

Authors

Masatoshi Kudo
Masatoshi KudoKanazawa UniversityRFRichard S. FinnAstraZeneca (United Kingdom)PGPeter R. GalleNational Council for Scientific and Technological Development

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kudo et al. (2022) studied this question.

synapsesocial.com/papers/69deaabd40ea065679558f7bhttps://doi.org/10.1159/000528272
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions2013 · 648 citations
  2. 2Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification1999 · 3,841 citations
  3. 3Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma2021 · 1,759 citations
  4. 4Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma2022 · 90 citations